Teva Pharmaceutical Industries Ltd. (commonly "Teva") is an Israeli-domiciled public company traded on the NYSE and TASE under the ticker TEVA. It was founded in 1901 and incorporated in Israel in 1944; global headquarters are at 124 Dvora HaNevi'a Street, Tel Aviv, with significant U.S. operations based in Parsippany/Woodcliff Lake, New Jersey. It reported revenue of $16,544 million for 2024 and approximately 37,000 employees across 57 markets in its 2024 annual report (third-party trackers put TTM revenue near $17.3B and headcount in the low 30,000s).
Products / operations. Teva is one of the world's largest generic-drug manufacturers, with generic products (including biosimilars) and active pharmaceutical ingredients, plus a specialty/innovative franchise. U.S. specialty products include AUSTEDO (tardive dyskinesia/Huntington's chorea), AJOVY (migraine), COPAXONE (multiple sclerosis), BENDEKA/TREANDA (oncology) and UZEDY; the company also operates the Anda generic-distribution business. It is an operating company with real manufacturing and commercial operations — not an NPE or shell licensor.
Patent-litigation posture. In the tracked data Teva appears in exactly one case, as a defendant (0 as plaintiff). That pattern is consistent with a large operating company being sued over drug patents rather than a patent assertion entity. The case is a Hatch-Waxman ANDA action, and the venue is the U.S. District Court for the District of New Jersey — Teva's home district and a common pharmaceutical forum — not a plaintiff-friendly patent venue such as the Eastern District of Texas.
Notable case. Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al. (D.N.J., filed July 8, 2011) involved Helsinn's antiemetic ALOXI (palonosetron hydrochloride). Teva Pharmaceuticals USA and Teva Pharmaceutical Industries were named defendants alongside Dr. Reddy's and Sandoz as ANDA filers. The litigation ultimately produced the Supreme Court's 2019 decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., which held that the AIA did not alter the scope of the on-sale bar. External context: Teva's generics scale expanded substantially with its 2016 acquisition of Allergan's generics business (Actavis).